Day One Biopharmaceuticals, Inc. $DAWN Shares Sold by NEOS Investment Management LLC

NEOS Investment Management LLC trimmed its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 84.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,542 shares of the company’s stock after selling 104,768 shares during the quarter. NEOS Investment Management LLC’s holdings in Day One Biopharmaceuticals were worth $138,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of DAWN. Federated Hermes Inc. acquired a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $39,000. Ameritas Investment Partners Inc. boosted its holdings in Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after acquiring an additional 2,264 shares during the last quarter. Entropy Technologies LP acquired a new position in Day One Biopharmaceuticals in the second quarter valued at $67,000. Prudential Financial Inc. purchased a new stake in Day One Biopharmaceuticals during the second quarter valued at about $69,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Day One Biopharmaceuticals during the second quarter worth about $76,000. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 15,459 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $179,324.40. Following the transaction, the chief executive officer owned 204,603 shares in the company, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Vasconcelles sold 2,728 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the transaction, the insider directly owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,461 shares of company stock worth $422,948 over the last three months. Insiders own 6.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DAWN shares. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. JPMorgan Chase & Co. raised their price target on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Piper Sandler increased their price objective on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $25.71.

Day One Biopharmaceuticals Trading Down 2.4%

NASDAQ DAWN opened at $11.78 on Friday. The stock has a market cap of $1.21 billion, a P/E ratio of -7.75 and a beta of -1.26. The company’s fifty day simple moving average is $10.48 and its 200-day simple moving average is $8.64. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.64 and a 52 week high of $13.20.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.